Literature DB >> 12056888

L-phenylalanine binding and domain organization in human phenylalanine hydroxylase: a differential scanning calorimetry study.

Matthías Thórólfsson1, Beatriz Ibarra-Molero, Peter Fojan, Steffen B Petersen, Jose M Sanchez-Ruiz, Aurora Martínez.   

Abstract

Human phenylalanine hydroxylase (hPAH) is a tetrameric enzyme that catalyzes the hydroxylation of L-phenylalanine (L-Phe) to L-tyrosine; a dysfunction of this enzyme causes phenylketonuria. Each subunit in hPAH contains an N-terminal regulatory domain (Ser2-Ser110), a catalytic domain (Asp112-Arg410), and an oligomerization domain (Ser411-Lys452) including dimerization and tetramerization motifs. Two partially overlapping transitions are seen in differential scanning calorimetry (DSC) thermograms for wild-type hPAH in 0.1 M Na-Hepes buffer, 0.1 M NaCl, pH 7.0. Although these transitions are irreversible, studies on their scan-rate dependence support that the equilibrium thermodynamics analysis is permissible in this case. Comparison with the DSC thermograms for truncated forms of the enzyme, studies on the protein and L-Phe concentration effects on the transitions, and structure-energetic calculations based on a modeled structure support that the thermal denaturation of hPAH occurs in three stages: (i) unfolding of the four regulatory domains, which is responsible for the low-temperature calorimetric transition; (ii) unfolding of two (out of the four) catalytic domains, which is responsible for the high-temperature transition; and (iii) irreversible protein denaturation, which is likely responsible for the observed exothermic distortion in the high-temperature side of the high-temperature transition. Stages 1 and 2 do not appear to be two-state processes. We present an approach to the analysis of ligand effects on DSC transition temperatures, which is based on the general binding polynomial formalism and is not restricted to two-state transitions. Application of this approach to the L-Phe effect on the DSC thermograms for hPAH suggests that (i) there are no binding sites for L-Phe in the regulatory domains; therefore, contrary to the common belief, the activation of PAH by L-Phe seems to be the result of its homotropic cooperative binding to the active sites. (ii) The regulatory domain appears to be involved in cooperativity through its interactions with the catalytic and oligomerization domains; thus, upon regulatory domain unfolding, the cooperativity in the binding of L-Phe to the catalytic domains seems to be lost and the value of the L-Phe concentration corresponding to half-saturation is increased. Overall, our results contribute to the understanding of the conformational stability and the substrate-induced cooperative activation of this important enzyme.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12056888     DOI: 10.1021/bi0160720

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  Ensemble perspective for catalytic promiscuity: calorimetric analysis of the active site conformational landscape of a detoxification enzyme.

Authors:  Matthew T Honaker; Mauro Acchione; John P Sumida; William M Atkins
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

Review 2.  Allosteric regulation of phenylalanine hydroxylase.

Authors:  Paul F Fitzpatrick
Journal:  Arch Biochem Biophys       Date:  2011-10-07       Impact factor: 4.013

3.  Combined spectroscopic and calorimetric characterisation of rubredoxin reversible thermal transition.

Authors:  Bárbara J Henriques; Lígia M Saraiva; Cláudio M Gomes
Journal:  J Biol Inorg Chem       Date:  2005-12-06       Impact factor: 3.358

4.  Thermal stability effects of removing the type-2 copper ligand His306 at the interface of nitrite reductase subunits.

Authors:  Andrea Stirpe; Luigi Sportelli; Hein Wijma; Martin Ph Verbeet; Rita Guzzi
Journal:  Eur Biophys J       Date:  2007-03-16       Impact factor: 1.733

5.  Structure of full-length human phenylalanine hydroxylase in complex with tetrahydrobiopterin.

Authors:  Marte Innselset Flydal; Martín Alcorlo-Pagés; Fredrik Gullaksen Johannessen; Siseth Martínez-Caballero; Lars Skjærven; Rafael Fernandez-Leiro; Aurora Martinez; Juan A Hermoso
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

6.  Folding dynamics of phenylalanine hydroxylase depends on the enzyme's metallation state: the native metal, iron, protects against aggregate intermediates.

Authors:  Aristobulo Loaiza; Judith A Ronau; Alexander Ribbe; Lia Stanciu; John W Burgner; Lake N Paul; Mahdi M Abu-Omar
Journal:  Eur Biophys J       Date:  2011-06-07       Impact factor: 1.733

7.  Metabolic phenotypes of phenylketonuria. Kinetic and molecular evaluation of the Blaskovics protein loading test.

Authors:  U Langenbeck; P Burgard; U Wendel; M Lindner; J Zschocke
Journal:  J Inherit Metab Dis       Date:  2009-07-16       Impact factor: 4.982

8.  Influence of the H-site residue 108 on human glutathione transferase P1-1 ligand binding: structure-thermodynamic relationships and thermal stability.

Authors:  Indalecio Quesada-Soriano; Lorien J Parker; Alessandra Primavera; Juan M Casas-Solvas; Antonio Vargas-Berenguel; Carmen Barón; Craig J Morton; Anna Paola Mazzetti; Mario Lo Bello; Michael W Parker; Luis García-Fuentes
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

9.  Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.

Authors:  Angel L Pey; Francois Stricher; Luis Serrano; Aurora Martinez
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

10.  Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.

Authors:  Søren W Gersting; Kristina F Kemter; Michael Staudigl; Dunja D Messing; Marta K Danecka; Florian B Lagler; Christian P Sommerhoff; Adelbert A Roscher; Ania C Muntau
Journal:  Am J Hum Genet       Date:  2008-06-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.